All In Biotech

Drug Trial Radar · NCT06385093

A Study on the Prevention and Treatment of GIOP With Eldecalcitol

Efficacy and Safety of Eldecalcitol in Preventing Glucocorticoid-induced Bone Loss in Rheumatoid Arthritis Patients (ELEGANT)

Last checked: Nov 20, 2026Latest source record: Apr 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 314 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

314

Planned (sponsor's estimate)

Start

Jun 2024

Primary completion

Dec 2025

Study completion Mar 2026

Sponsor

Lead sponsor
Chinese SLE Treatment And Research GroupAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Beijing Life oasis public service center
First posted
Apr 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will be a multi-center, randomized, open label, parallel trial conducted in rheumatoid arthritis patients treated with glucocorticoids. After signing the informed consent, all patients will be screened as per the inclusion and exclusion criteria. Estimated 314 eligible patients will be enrolled. The enrolled patients will be randomly assigned to either Eldecalcitol group or Alfacalcidol group in a 1:1 ratio and followed up for 12 months. On-site follow up visits will be conducted at Month 6 and 12 after enrollment. The study is designed to evaluate the efficacy and safety of Eldecalcitol in preventing glucocorticoid-induced bone loss in rheumatoid arthritis patients.

Conditions

  • Rheumatoid Arthritis
  • Osteoporosis
  • Osteopenia

Interventions

  • Eldecalcitol capsulesDrug

    Oral eldecalcitol 0.75μg daily

  • Alfacalcidol tabletsDrug

    Oral Alfacalcidol 0.5μg daily

  • Calcium carbonate tabletsDrug

    1.5g Calcium carbonate daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline to month 12 in lumbar spine (L1-4) bone mineral density (BMD)Time frame: Baseline and 12 months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Aerospace Central Hospital

    Beijing, Beijing Municipality, China

  • Beijing Luhe hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Beijing Shijingshan Hospital

    Beijing, Beijing Municipality, China

  • Beijing Shijitan Hospital

    Beijing, Beijing Municipality, China

  • Beijing Shunyi hospital

    Beijing, Beijing Municipality, China

  • Xuanwu Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.